Published in final edited form as:

Mol Neurobiol. 2008 August ; 38(1): 66–77. doi:10.1007/s12035-008-8034-z.

Membrane Estrogen Receptors Acting Through Metabotropic Glutamate Receptors: An Emerging Mechanism of Estrogen Action in Brain

Paul E. Micevych and

Department of Neurobiology and Laboratory of Neuroendocrinology of the Brain Research Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA, e-mail: pmicevych@mednet.ucla.edu

Paul G. Mermelstein

Department of Neuroscience, University of Minnesota, 6-145 Jackson Hall, 321 Church St. S.E., Minneapolis, MN 55455, USA, e-mail: pmerm@umn.edu

Abstract

It has been over 60years since the first studies have been published describing the effects of steroid hormones on brain function. For over 30years, estrogen has been presumed to directly affect gene expression and protein synthesis through a specific receptor. More than 20years ago, the first estrogen receptor was cloned and identified as a transcription factor. Yet, throughout their course of study, estrogens have also been observed to affect nervous system function via mechanisms independent of intracellular receptor regulation of gene expression. Up until recently, the membrane estrogen receptors responsible for these rapid actions have remained elusive. Recent studies have demonstrated that a large number of these rapid, membrane-initiated actions of estradiol are due to surface expression of classical estrogen receptors. This review focuses on the importance of membrane estrogen receptor interactions with metabotropic glutamate receptors for understanding rapid estradiol signaling mechanisms and downstream effectors, as well as their significance in a variety of physiological processes.

Keywords

Estradiol; mGluR; Lordosis; Nociception; Pain; Estrous cycle; Membrane; Rapid actions

Introduction

For more than 60years, researchers have studied the effects of steroid hormones on brain function [1]. From the outset, it was clear that hormones such as estrogens could profoundly affect development as well as adult behavior. To understand the mechanism(s) by which estrogens act within the central nervous system, initial experimenters utilized steroid autoradiography techniques [2,3]. This method identified brain regions in which the steroid would bind, thus presumptive sites of estrogen receptor expression. Areas of the brain identified by this technique included the hypothalamus, pituitary, and preoptic area, amongst others, which, based on a series of lesion and stimulation studies, were known to affect physiology and behaviors related to endocrine function [4]. The yet to be characterized estrogen receptor was presumed to affect gene expression, as estrogen action on the central control of

reproduction was dependent on the transcription of new protein [5,6]. With the cloning of the first estrogen receptor [7,8], our ability to study estrogen receptor function greatly expanded.

The distribution of estrogen receptor messenger RNA (mRNA), especially the receptor now known as estrogen receptor- α (ER α), within the nervous system [9,10] confirmed steroid autoradiography studies [2,3]. Furthermore, ER α was characterized as an intracellular, ligand-regulated transcription factor [11]. As such, ER α is located primarily in the nucleus [12,13]. Once bound to estradiol, ER α dimers were shown to regulate gene expression via action at estrogen response elements (EREs) [14].

These ER α -mediated changes in gene expression and protein synthesis are commonly referred to as the classical mechanism of estrogen action. Following a series of discoveries, this classical mechanism required further refinement, including the identification of a second, but structurally related, estrogen receptor (estrogen receptor- β , ER β) [15]; ER regulation of transcription factor and co-factor interactions [16,17]; and ER regulation of gene transcription independent of EREs. This latter finding provided an explanation for why the selective estrogen receptor mediator, tamoxifen, had both antagonistic and agonistic properties, albeit in different tissues. ERs can stabilize the binding of Fos and Jun to the AP-1 site [18]. In such tissues, tamoxifen acts as a receptor agonist. When tamoxifen acts as an antagonist, a classic ER-ERE interaction is present [18]. Finally, estrogen receptors have also been shown to act in the absence of estrogens [19,20], adding another layer of transcriptional complexity.

Classical Versus Novel Mechanisms of Estrogen Action

With the identification of a clearly defined receptor that localized to brain regions that are both sensitive to estradiol as well as being critical to neuroendocrine function, the fundamental question of how estrogen acts on the brain seemed to be answered. Further supporting this notion of estradiol action in the nervous system were the parallel findings in endocrine tissue [21,22]. However, as far back as 30–40 years, studies described phenomena that could not be explained by the classical mechanism of estrogen action. When the first reports of extremely rapid effects of estrogens were published, they were met with great skepticism. And while today there is general agreement that these novel actions of estradiol are real, there are still many questions and controversies that remain regarding the exact mechanism(s) by which these effects occur and their physiological relevance.

As alluded to in the previous paragraph, for many years, the principal defining feature of a non-classical or novel effect of estrogen was the timing in which a response to steroid application could first be measured. One of the first reported, non-classical effects of estrogens was on the accumulation of cAMP in uterine tissue. Clara Szego and June Davis reported that concentrations of cAMP increased within 15s of estrogen application [23]. In neurons, Robert Moss and Martin Kelly were the main proponents of estradiol having rapid effects. They showed that within seconds, the hormone altered the electrical activity of preoptic and septal neurons [24]. Since then, modification of cell excitability through modulation of ion channels has been observed in various other brain regions [25–27]. Another term often used to distinguish between classical and novel actions of estradiol has been genomic versus non-genomic effects. This definition was once popular because novel actions of estrogens were thought to be limited to transient alterations in cell excitability. Today, we know this not to be the case, as estradiol through novel mechanisms can affect gene expression and protein synthesis through the activation of transcription factors such as cAMP response element-binding protein (CREB) [28–31]. It should also be mentioned that, while the timing of estradiol action was also once thought to clearly differentiate between classical and novel effects of the hormone, this line has also been blurred. It was previously considered that classical actions of estradiol required hours for the onset of an observable effect, with durations of action lasting for days. In contrast, novel effects appeared to be much more rapid with effects observable in

seconds to minutes and present only for the duration of hormone application. With more powerful and sensitive scientific techniques, classical actions of estradiol can be observed within minutes. A similar convergence has occurred with estradiol action ascribed to novel receptors. Novel estradiol actions are now known to activate transcriptional events that have long-term consequences on nervous system function that far exceed the duration of estradiol application.

A common criticism of membrane actions is that they often require higher concentrations of estradiol than the traditional transcriptional regulation. These estradiol levels have been characterized as non-physiological or, less charitably, pharmacological and even toxicological. The issue of steroid concentration needed to activate membrane receptors is a difficult one to deal with since estradiol concentrations needed to activate membrane receptors is usually two to three orders of magnitude above peak circulating levels in vivo. There are several possible explanations for this. One idea suggests that, while in the membrane, the estrogen receptor steroid binding site is constrained, requiring higher levels of estradiol for binding [32]. Another proposes that the membrane ER may act as a sensor to detect changes in estradiol concentration rather than the absolute level. Still another idea based on classic G protein-coupled receptor (GPCR) physiology is that, although the binding affinity of a receptor may be relatively low, the concentration of ligand needed to elicit a cellular response is somewhat less than predicted by binding studies due to the non-linear nature of GPCR signaling [33]. However, as methods for examining these membrane effects of estradiol become more refined, the concentrations needed to elicit an effect have approached or even matched the K_d of the intracellular receptor [27,28,34,35]. Finally, this discussion may be moot since brain concentrations of estradiol are not actually known. Indeed, there are suggestions that local estradiol concentrations in hypothalamus are much higher than in the circulation [36]. The lipid-rich brain environment may depot estradiol that is slowly released, and testosterone may be aromatized locally—raising local estradiol concentration into the range that stimulates various membrane ER processes.

Along with the ‘classical’ and ‘novel’ nomenclature used to classify these two modes of estradiol action, there is a second, more descriptive terminology. While classical effects require the activation of intracellular receptors, novel actions appear to be initiated at the membrane surface. This has been typically determined through the utilization of membrane impermeable estrogen analogs [37,38]. The persistence of a novel action of estradiol following the intracellular dialysis of a cell with the steroid also supports this mechanism of action [27]. Following this logic, estradiol would require the expression of an estrogen receptor on the cell membrane. Pietras and Szago [39] first demonstrated estradiol binding to endothelial cell membranes, suggesting a putative membrane ER, but because there was no indication that a novel molecule bound estradiol at the membrane, these results languished. Since this initial investigation, the numerous reports of membrane localization of ER α and ER β were argued to be artifact and thus often dismissed out of hand. The idea behind such arguments was that an ER in the membrane must be a completely different protein. In 1999, overexpression of ER α and ER β revealed that a portion of the classic ER protein was targeted to the membrane and activated intracellular signaling [40]. This simple and elegant experiment demonstrated that the same protein is capable of mediating both intracellular and membrane actions of estradiol.

One often studied indication of rapid estradiol action has been the phosphorylation (activation) of CREB [29,31,41,42]. Phosphorylation of CREB is an important node in cell signaling, critically involved in various forms of neuronal plasticity. Several laboratories have found that the activation of surface estrogen receptors leads to CREB phosphorylation via stimulation of the mitogen-activated protein kinase (MAPK) or externally regulated kinase signaling pathway. In turn, activated CREB regulates gene expression through interaction with DNA at CREB response elements (CREs). These and other novel estradiol actions are blocked by the

ER antagonist ICI 178,820, whereas ER α and ER β agonists frequently mimic the actions of the steroid [28,43]. Such results provided pharmacological evidence that classical ERs play a role in the novel actions of estradiol. While these data still provide room to argue for a unique membrane estrogen receptor, debate whether classical estrogen receptors were at least partially responsible for mediating some of the reported rapid effects essentially ended when Alan Herbison and colleagues, using ER knockout mice, determined that the rapid actions of estradiol on phosphorylation of CREB and MAPK were dependent on ER α or ER β [44]. However, with the end of one controversy, another quickly surfaced: That is, how do classical ERs, known to be transcription factors, initiate cell signaling when inserted in the membrane? Moreover, how are ERs trafficked and inserted into the membrane?

Estrogen Receptor Interactions with mGluRs

Clues to the mechanism by which membrane-localized ER α and ER β exert effects on cell function included numerous reports that describe estrogen action to be sensitive to G-protein manipulation. Based upon these data, a relatively straightforward hypothesis, i.e., ER α and ER β directly bind and activate G-proteins, was put forth [45,46]. Although temptingly straightforward, this hypothesis does not address the myriad of cell signaling cascades activated by estradiol. Moreover, G protein receptors as a family are characterized as integral membrane proteins with a conserved structure that includes seven transmembrane helices. The structure of estrogen receptors does not resemble the consensus structure of GPCRs. Based on these issues, we chose to examine another possibility. What if ERs interact with and activate known GPCRs. While in some respects this just alters the basic deficiency in our knowledge (i.e., how estrogen receptors activate GPCRs), there is accumulating evidence that estrogen receptors are capable of trans-activating surface membrane proteins.

Our recent findings provide evidence for such an alternative explanation for ER α and ER β regulation of G-protein signaling. In various cells of the nervous system, we find ER α and ER β to activate metabotropic glutamate receptors (mGluRs). mGluRs are a family of GPCRs that, when binding glutamate, initiate G protein signaling. Three groups of mGluRs have been identified based on sequence homology and second messenger linkage. mGluR1 and mGluR5 comprise the group I mGluRs and are coupled to Gq. In contrast, group II mGluRs are the mGluR2 and mGluR3 receptors that activate Gi/Go signaling. mGluR4, mGluR6, mGluR7, and mGluR8 comprise the group III mGluRs, which are also Gi/Go-coupled. Activation of group I mGluRs has been demonstrated to phosphorylate CREB through the same signaling pathway as estradiol [47,48]. Consequently, in cultured hippocampal neurons, estradiol-induced MAPK-dependent CREB phosphorylation was dependent on membrane estrogen receptor stimulation of mGluR1. In addition, L-type calcium channel-dependent CREB phosphorylation (in this case, CREB is phosphorylated by calmodulin-dependent protein kinase IV, CaMKIV) was attenuated by estrogen receptor activation of group II mGluRs [28]. This action of estradiol in hippocampal tissue was only found in neurons generated from female and not male tissue.

We subsequently determined that estrogen receptor interactions with mGluRs are dependent upon caveolin proteins [34], known to be essential for the trafficking and clustering of signaling molecules. The importance of caveolin proteins in the trafficking of ER α to the membrane was first demonstrated outside of the nervous system [49] and in which palmitoylation of the ER was also required [50,51]. ER interactions with caveolins and mGluRs do not appear random. In hippocampal neurons, ER α interaction with either mGluR1 or mGluR2/3 was dependent upon either caveolin 1 (CAV1) or caveolin 3 (CAV3), respectively. Conversely, ER β only interacted with mGluR2/3 via CAV3. The pairing of particular ERs with mGluRs is observed in various other brain regions. For example, ER α is associated with mGluR1 in hypothalamic neurons in vivo [52], whereas ER β activation of mGluR2/3 has been observed in dorsal root

ganglia [53]. Similarly, rapid estradiol signaling in astrocytes is also dependent on mGluR1a [54].

More recently, we have found that ER α via CAV1 activates mGluR5-based signaling in striatal neurons [55]. This is of particular interest because striatal neurons express both group I mGluRs, mGluR1 and mGluR5. In striatal neurons, mGluR1 signaling was unaffected by estradiol. Upon further study, hippocampal neurons also demonstrate functional coupling of mGluR1 and mGluR5 to CREB. Yet, estradiol does not affect mGluR5 signaling in the hippocampus (Boulware and Mermelstein, unpublished). It remains to be determined why, across different neuronal populations, ERs would be paired with discrete types of mGluRs that are known to activate the same second messenger systems.

Functional isolation of different ERs with mGluRs suggests a diverse array of potential estrogen-sensitive signaling pathways at the disposal of individual cells (Fig. 1). The generation of specific ER/mGluR pairs via caveolin function may eventually be found to be responsible for many of the diverse observations of novel estrogen signaling in the central nervous system. And while the question as to how ER α and ER β activate GPCRs remains to be answered, there are previous precedents that provide the basis of a potential mechanism.

It is our working hypothesis that ERs activate mGluRs through a direct protein–protein interaction. Upon estradiol binding to the ER, a conformational change, similar to what occurs when glutamate binds the receptor, results in mGluR activation of the G-protein and initiation of second messenger signaling. In non-neuronal tissue, estrogen receptors have been found to directly bind tyrosine kinase receptors [56], which are in turn activated following estrogen application [57]. This common mechanism of ER to surface receptor activation may account for the novel actions of estradiol outside of the brain, as mGluR expression is nervous system-specific. Notably, this does not preclude the converse possibility, i.e., that ERs interact with tyrosine kinase receptors in the central nervous system (CNS) as well. Indeed, these interactions occur in the hypothalamus to influence reproduction [58] as well as in the substantia nigra where it appears to mediate neuroprotection [59]. In terms of evidence for this putative mechanism, co-immunoprecipitation experiments suggest that ERs can directly interact with mGluRs [52] (Fig. 2a). In vivo experiments utilizing an mGluR agonist and an estrogen receptor antagonist strongly suggest that an ER/mGluR protein–protein interaction can alter the function of mGluR signaling. Figure 2b examines CREB phosphorylation following the activation of mGluR1 with (*S*)-3,5-dihydroxyphenylglycine (DHPG), a selective group I mGluR agonist. Activation of CREB by DHPG is attenuated following the application of the estrogen receptor antagonist. This action of ICI 182,780 does not appear due to a direct effect on mGluR1; as in cultures from male animals that lack an estrogen response, ICI does not influence the actions of DHPG. Future research will need to determine more definitively the mechanism by which ERs activate mGluRs.

Physiological Aspects of Rapid Estradiol Signaling

One of the continuing controversies of rapid, membrane-initiated actions of estradiol relates to their physiological significance. That is, it has been argued that the classical mechanism of estradiol action can account for all estrogen-regulated behaviors. Yet, here we describe three separate estrogen-sensitive processes that require a “novel” mechanism of estrogen action: regulation of lordosis, neuroprogesterone synthesis and its influence on the hypothalamic–pituitary–gonadal (HPG) axis, and signaling in dorsal root ganglion (DRG) neurons associated with nociception. In all three systems, we find a rapid component of estradiol that is dependent upon ER/mGluR signaling.

Sexual Receptivity—Arguably, the best studied and most robust actions of estradiol in the brain have been on neural circuits controlling the HPG axis that regulate reproduction. Thus,

it is appropriate to study the physiology of rapid estradiol actions in the brain within the context of reproduction. In the female rat, estradiol acts on a limbic–hypothalamic circuit to allow the expression of lordosis, a stereotypic sexually receptive behavior [60,61]. Although lordosis can be elicited by implanting estradiol directly into the hypothalamus [62,63], attempts to induce lordosis behavior exclusively through membrane actions of estradiol have not been successful. The assumption is that gene transcription is needed to elicit lordosis behavior. During the estrous cycle, estradiol rises slowly over several days before peaking on the afternoon of proestrus in rodents prior to the onset of sexual receptivity. Estradiol given at relatively low doses, without additional supplemental estradiol, will induce lordosis behavior approximately 48h later. It has been known for almost 30years that estradiol-induced lordosis behavior is dependent on the transcription of new proteins [6,64]. As expected, a host of reproductively important neuropeptide mRNAs and proteins have been shown to be increased by estradiol [65–71]. To a first approximation, estradiol induction of female sexually receptive behavior has a time course that strongly implicates transcriptional actions of estradiol. However, priming animals with a membrane-constrained estradiol (E-6-BSA) followed with a subthreshold dose of estradiol was as efficacious as two estradiol injections [72]. The interpretation favored by those authors is that rapid estradiol signaling facilitates nuclear ER-stimulated transcriptional events, suggesting cooperation between nuclear- and membrane-initiated actions of estradiol. These results indicated that rapid actions participated in the control of sexual receptivity but did not offer a mechanism through which these rapid actions were initiated.

To examine the rapid estradiol component involved in the facilitation of lordosis, we studied estradiol activation as a part of the extensive limbic–hypothalamic lordosis regulating circuit, involving a β -endorphin projection from the arcuate nucleus to the medial preoptic nucleus [73]. A hallmark of this circuit being activated is the rapid internalization of μ -opioid receptors (MOR) in the medial preoptic area that are associated with the regulation of lordosis behavior [74,75]. Without MOR activation, lordosis is significantly attenuated [76,77]. Further indication that this was a membrane-initiated estradiol action was obtained by facilitating lordosis behavior with administration of E-6-BSA directly into the arcuate nucleus. In the arcuate nucleus, ER α was colocalized with mGluR1a. Furthermore, the membrane fraction of ER α co-immunoprecipitated with mGluR1a, suggesting a potential functional association between these receptors [52]. When mGluR1a is blocked, estradiol-induced lordosis is attenuated. Interestingly, this blockade is only effective at the time of estradiol treatment and not several hours after estradiol, further suggesting that mGluR1 signaling is directly related to the rapid action of estradiol.

Our understanding of how the ER/mGluR interaction mediates behavior is illustrated in Fig. 3. Low systemic estradiol levels are insufficient to elicit lordosis behavior. The arcuate–medial preoptic circuit is quiescent. Membrane ERs in the arcuate nucleus are not stimulated, which is reflected by the cellular distribution of MOR in the medial preoptic area. The majority of MORs are localized on the cell membrane, indicating that these receptors have not been activated. In these conditions, the female rat is not sexually receptive (Fig. 3a). However, when systemic estradiol reaches levels that induce behavior, membrane ERs in the arcuate nucleus are activated, leading to MOR internalization and subsequent full lordosis behavior (Fig. 3b). Accordingly, when mGluR1a is directly stimulated with an agonist under low estradiol conditions, membrane ERs can be bypassed, resulting in MOR internalization and facilitation of lordosis (Fig. 3c). Conversely, under high estrogenic conditions, antagonizing mGluR1a blocks estrogen-induced MOR internalization and attenuates sexual behavior (Fig. 3d). These data are consistent with the *in vitro* demonstration of ER α /mGluR1a signaling in hippocampal neurons and provided the first *in vivo* evidence that estradiol can signal through activation of mGluR1a. By demonstrating that lordosis behavior, a classical assay of estradiol action, has a

rapid non-genomic component underscores the importance of ER/mGluR interactions in the brain [52].

Neuroprogesterone Synthesis—With respect to the LH surge, the most effective estradiol replacement strategies rely on a long time course, in excess of 48h [78], which is not compatible with rapid actions of estradiol. However, a number of tantalizing hints that the rapid effects of estradiol influence the estrous cycle have emerged over the years. Kelly and his colleagues have identified a number of rapid actions of estradiol, including regulation of potassium channels, activation of protein kinase C and protein kinase A pathways, and uncoupling μ -opioid receptors from GABA_B receptors in guinea pig GnRH neurons [79]. Whether these actions are related to GnRH release is not yet known. In addition to these possible interactions, we have proposed a neurosteroid-based hypothesis to help understand the interaction between circulating estradiol and neuroprogesterone, progesterone synthesized de novo from cholesterol by the brain [80].

The brain, like the gonads and adrenal cortex, is a steroidogenic organ. All of the necessary steroidogenic enzymes and activities needed to synthesize sex steroids from cholesterol have been isolated in various parts of the brain [81]. One of the most intriguing steroids synthesized in the brain is neuroprogesterone. In addition to the myriad of progesterone-mediated actions, its metabolite, allopregnenalone, has profound effects on neuronal excitation through actions at the GABA_A receptor [82,83]. Neuroprogesterone itself has been shown to control aspects of reproduction [80]. The capacity of steroidogenesis in the cells of the CNS is widespread, but different cell types appear to preferentially produce specific steroids [84]. Progesterone is the preferred product of astrocytes [85,86]. Interestingly, the synthesis of progesterone is widely distributed in the rat brain, with measurable levels in the hypothalamus, cortex, hippocampus, medulla, and cerebellum. Within the adult female rat hypothalamus, estradiol stimulates the synthesis of progesterone [87]. Since we were interested in understanding the interaction between circulating estradiol and neuroprogesterone synthesis, we treated primary astrocyte cultures with estradiol. Estradiol rapidly increased free cytoplasmic calcium influx by releasing intracellular stores of calcium [25]. This calcium influx is dependent on activation of the phospholipase C/inositol trisphosphate (PLC/IP₃) pathway and was blocked by an inhibitor of the IP₃ receptor. Similarly, estradiol increased the synthesis of progesterone that was dependent on a robust calcium influx [85]. To mimic the actions of estradiol on releasing IP₃ receptor-sensitive intracellular calcium stores, thapsigargin was used to induce the release of intracellular calcium. The effect was a stimulation of progesterone synthesis that was as robust as estradiol. Moreover, the increase of progesterone synthesis was seen after 1h of treatment, the earliest time point examined [85]. Thus, in astrocytes, like in ovarian cells, the stimulation of progesterone synthesis is dependent on calcium.

In the ovary, G protein-coupled gonadotropin receptors induce the calcium influx [88–91], but in the brain, it is estradiol that mobilizes calcium [25]. As in the arcuate nucleus, the mGluR1a antagonist LY367385 blocked estradiol-induced calcium influx, suggesting that, in astrocytes, the same ER-mGluR1a signaling was the result of an interaction between membrane ER and mGluR1a [54]. Further evidence of such an interaction is the co-immunoprecipitation of ER α and mGluR1a in the membrane fraction of astrocytes. Interestingly, while both estradiol and DHPG (a group I mGluR agonist) alone produced a robust influx of calcium, neither was as effective alone as they were together, indicating that for maximal signaling in astrocytes both glutamate and estradiol need to be present. These results suggest that estradiol may act most effectively on astrocytes that are near active glutamatergic terminals (Fig. 4).

Adenosine Triphosphate Signaling in DRG Neurons—The cell bodies of primary visceral spinal afferent neurons are located in the DRG. Primary afferents transmit information about chemical or mechanical stimulation from the periphery to the spinal cord. Nociceptors

are small to medium size DRG neurons whose peripheral processes detect potentially damaging physical and chemical stimuli. One such signal is adenosine triphosphate (ATP), which has emerged as a putative signal for visceral pain. Noxious stimuli such as distention of the viscera or tissue damage release ATP [92]. ATP transduces noxious stimuli by activating purinergic, ATP-gated P2X receptors on primary afferent fibers [93]. Opening of P2X channels results in membrane depolarization sufficient to trigger action potentials and calcium influx through voltage-gated calcium channels (VGCC) associated with nociception [94]. According to this theory, the pain of tissue irritation (mechanical distortion or inflammation) is due to ATP activation of high threshold nociceptors [92,95]. The predominant ATP receptor in small diameter nociceptive DRG neurons is the P2X₃ [96,97]. P2X₃-null mice have reduced pain-related behavior in response to noxious stimuli [98,99].

Several lines of evidence indicate that estradiol directly influences the function of primary afferent neurons. Both ER α and ER β are present in DRG neurons including the small- to medium-diameter putative nociceptors [100]. In vitro, 85% of the ATP-sensitive DRG neurons respond to estradiol [101], which correlates well with the idea that visceral afferents are estradiol-sensitive. Evidence for this supposition include (1) visceral pain is affected by hormonal levels in cycling females [102–104], (2) there are sex differences in the prevalence of functional disorders involving the viscera [105,106], and (3) putative visceral afferents [107] fit into the population of DRG neurons that are sensitive to estradiol [101]. These data suggest that, in addition to central actions of estradiol [108], estradiol can also act in the periphery to modulate nociception. ERs are distributed in regions of the central and peripheral nervous system that mediate nociception. For example, ERs are expressed in dorsal horn neurons of the spinal cord [109,110] and DRG neurons [100,111,112]. Estradiol acts in neurons to modulate L-type VGCC [27,101,113]. Recent studies demonstrate that estradiol has a significant role in modulating visceral sensitivity, indicating that estradiol alterations in sensory processing may underlie sex-based differences in functional pain symptoms [114]. However, reports of estradiol modulation of visceral and somatic nociceptive sensitivity are inconsistent. For example, elevated estradiol levels have been reported to increase the threshold to cutaneous stimuli [115] but decrease the percentage of escape responses to ureteral calculosis [116]. On the other hand, nociceptive sensitivity appears to increase when estradiol levels are elevated [117]. Indeed, in most clinical studies, women report more severe pain levels, more frequent pain, and longer duration of pain than men [118,119].

In a primary culture of DRG neurons, estradiol inhibited the ATP-mediated calcium influx in 85% small-diameter ATP-responsive DRG neurons. A dose–response curve demonstrated that the estradiol action was stereospecific and inhibited by ER antagonists tamoxifen and ICI 162,780. The cellular calcium response initiated by ATP has two components. The initial ion flux is through activated P2X channels, and the secondary response is the opening of VGCC in response to membrane depolarization [94]. The entire calcium transient was blocked with the purine receptor antagonist pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid, but the calcium response was only partially inhibited by estradiol, suggesting that estradiol did not directly antagonize P2X receptors. Specific VGCC channel blockers were used to characterize the VGCC blocked by estradiol. Nifedipine, an L-type VGCC blocker significantly attenuated the ATP-induced calcium influx. Furthermore, estradiol treatment did not result in additional inhibition, suggesting that estradiol acts on L-type VGCC. This result is consistent with an estradiol blockade of L-type calcium channels in PC-12 cells [120], neostriatal, and hippocampal neurons [27,121]. ER α is needed for the estradiol attenuation of ATP-induced calcium influx as demonstrated by a lack of response to estradiol in DRG neurons from ER α knockout (ER α KO) mice. The estradiol response is retained in ER β knockout (ER β KO) mice [122].

ER α interacts, in a tissue-specific manner, with mGluR2/3 [28,34]. To determine if the estradiol inhibition of ATP-induced Ca² signaling required mGluR2/3, astrocytes were stimulated with ATP, washed, and then re-stimulated in the presence of estradiol or estradiol and the mGluR2/3 antagonist LY341495 [53]. The estradiol attenuation of ATP-mediated calcium influx was blocked by LY341495. Thus, rapid estradiol inhibition of calcium influx in DRG neurons is dependent on mGluR2/3.

Conclusions

Clearly, we are in the initial stages of understanding when and how rapid estradiol actions fit into the physiologic context of estradiol actions in the nervous system. Yet, recent findings suggest a mechanism by which ERs in the membrane can elicit changes in cell signaling and several different systems in which the actions of estradiol on membrane ERs require an interaction with mGluRs. This mechanism of ER–mGluR interactions provides a framework through which the pleiomorphic membrane-initiated estradiol actions can be understood and used to elucidate various means by which ERs play an important role in brain function.

Acknowledgements

This work was supported by NIH grants DA013185 and HD042635 (PEM) and NS41302 (PGM). The authors would like to thank Dr. Marissa Boulware for providing the experimental data found within this review and Jessie Luoma for her technical assistance regarding the preparation of this manuscript.

References

1. Beach, F. Hormones and behavior. Hoeber; New York: 1948.
2. Pfaff D, Keiner M. Atlas of estradiol-concentrating cells in the central nervous system of the female rat. *J Comp Neurol* 1973;151:121–158. [PubMed: 4744471]
3. Stumpf WE, Sar M. Steroid hormone target sites in the brain: the differential distribution of estrogen, progesterin, androgen and glucocorticosteroid. *J Steroid Biochem* 1976;7:1163–1170. [PubMed: 1025363]
4. Pfaff, DW.; Schwartz-Giblin, S.; McCarthy, MM.; Kow, L-M. Cellular and molecular mechanisms of female reproductive behaviors. In: Neill, JD., editor. *Physiology of reproduction*. Elsevier; Amsterdam: 2006. p. 107-220.
5. Gorski RA, Gordon JH, Shryne JE, Southam AM. Evidence for a morphological sex difference within the medial preoptic area of the rat brain. *Brain Res* 1978;148:333–346. [PubMed: 656937]
6. Rainbow TC, Davis PG, McEwen BS. Anisomycin inhibits the activation of sexual behavior by estradiol and progesterone. *Brain Res* 1980;194:548–555. [PubMed: 7388631]
7. Koike S, Sakai M, Muramatsu M. Molecular cloning and characterization of rat estrogen receptor cDNA. *Nucleic Acids Res* 1987;15:2499–2513. [PubMed: 3031601]
8. Spreafico E, Bettini E, Pollio G, Maggi A. Nucleotide sequence of estrogen receptor cDNA from Sprague–Dawley rat. *Eur J Pharmacol* 1992;227:353–356. [PubMed: 1473557]
9. Shughrue PJ, Komm B, Merchenthaler I. The distribution of estrogen receptor-beta mRNA in the rat hypothalamus. *Steroids* 1996;61:678–681. [PubMed: 8987135]
10. Simerly RB, Chang C, Muramatsu M, Swanson LW. Distribution of androgen and estrogen receptor mRNA-containing cells in the rat brain: an in situ hybridization study. *J Comp Neurol* 1990;294:76–95. [PubMed: 2324335]
11. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. *Endocr Rev* 1999;20:321–344. [PubMed: 10368774]
12. King WJ, Greene GL. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. *Nature* 1984;307:745–747. [PubMed: 6700704]
13. Welshons WV, Lieberman ME, Gorski J. Nuclear localization of unoccupied oestrogen receptors. *Nature* 1984;307:747–749. [PubMed: 6700705]

14. O'Malley BW, Tsai MJ. Molecular pathways of steroid receptor action. *Biol Reprod* 1992;46:163–167. [PubMed: 1536890]
15. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. *Proc Natl Acad Sci U S A* 1996;93:5925–5930. [PubMed: 8650195]
16. Lonard DM, Tsai SY, O'Malley BW. Selective estrogen receptor modulators 4-hydroxytamoxifen and raloxifene impact the stability and function of SRC-1 and SRC-3 coactivator proteins. *Mol Cell Biol* 2004;24:14–24. [PubMed: 14673139]
17. Xu J, Liao L, Ning G, Yoshida-Komiya H, Deng C, O'Malley BW. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. *Proc Natl Acad Sci U S A* 2000;97:6379–6384. [PubMed: 10823921]
18. Uht RM, Anderson CM, Webb P, Kushner PJ. Transcriptional activities of estrogen and glucocorticoid receptors are functionally integrated at the AP-1 response element. *Endocrinology* 1997;138:2900–2908. [PubMed: 9202234]
19. Han F, Miksicek R, Clarke R, Conrad SE. Expression of an estrogen receptor variant lacking exon 3 in derivatives of MCF-7 cells with acquired estrogen independence or tamoxifen resistance. *J Mol Endocrinol* 2004;32:935–945. [PubMed: 15171723]
20. Zava DT, Chamness GC, Horwitz KB, McGuire WL. Human breast cancer: biologically active estrogen receptor in the absence of estrogen? *Science* 1977;196:663–664. [PubMed: 193182]
21. Luz NP, Marques M, Ayub AC, Correa PR. Effects of estradiol upon the thymus and lymphoid organs of immature female rats. *Am J Obstet Gynecol* 1969;105:525–528. [PubMed: 5824869]
22. Sanfilippo O, Daidone MG, Di Fronzo G, Silvestrini R. Short-term tissue culture of human breast cancer: presence of estrogen receptors and 17 beta-estradiol stimulation of RNA synthesis. *Cancer* 1979;43:2365–2369. [PubMed: 455226]
23. Szego CM, Davis JS. Adenosine 3',5'-monophosphate in rat uterus: acute elevation by estrogen. *Proc Natl Acad Sci U S A* 1967;58:1711–1718. [PubMed: 4295833]
24. Kelly MJ, Moss RL, Dudley CA. Differential sensitivity of preoptic-septal neurons to microelectrophoresed estrogen during the estrous cycle. *Brain Res* 1976;114:152–157. [PubMed: 986858]
25. Chaban VV, Lakhter AJ, Micevych P. A membrane estrogen receptor mediates intracellular calcium release in astrocytes. *Endocrinology* 2004;145:3788–3795. [PubMed: 15131017]
26. Joels M. Steroid hormones and excitability in the mammalian brain. *Front Neuroendocrinol* 1997;18:2–48. [PubMed: 9000458]
27. Mermelstein PG, Becker JB, Surmeier DJ. Estradiol reduces calcium currents in rat neostriatal neurons via a membrane receptor. *J Neurosci* 1996;16:595–604. [PubMed: 8551343]
28. Boulware MI, Weick JP, Becklund BR, Kuo SP, Groth RD, Mermelstein PG. Estradiol activates group I and II metabotropic glutamate receptor signaling, leading to opposing influences on cAMP response element-binding protein. *J Neurosci* 2005;25:5066–5078. [PubMed: 15901789]
29. Gu G, Rojo AA, Zee MC, Yu J, Simerly RB. Hormonal regulation of CREB phosphorylation in the anteroventral periventricular nucleus. *J Neurosci* 1996;16:3035–3044. [PubMed: 8622133]
30. Szego EM, Barabas K, Balog J, Szilagyi N, Korach KS, Juhasz G, Abraham IM. Estrogen induces estrogen receptor alpha-dependent cAMP response element-binding protein phosphorylation via mitogen activated protein kinase pathway in basal forebrain cholinergic neurons in vivo. *J Neurosci* 2006;26:4104–4110. [PubMed: 16611827]
31. Wade CB, Dorsa DM. Estrogen activation of cyclic adenosine 5'-monophosphate response element-mediated transcription requires the extracellularly regulated kinase/mitogen-activated protein kinase pathway. *Endocrinology* 2003;144:832–838. [PubMed: 12586759]
32. Okamura WH, Midland MM, Hammond MW, Abd Rahman N, Dormanen MC, Nemere I, Norman AW. Chemistry and conformation of vitamin D molecules. *J Steroid Biochem Mol Biol* 1995;53:603–613. [PubMed: 7626517]
33. Selley DE, Liu Q, Childers SR. Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP gamma S binding in mMOR-CHO cells and rat thalamus. *J Pharmacol Exp Ther* 1998;285:496–505. [PubMed: 9580589]

34. Boulware MI, Kordasiewicz H, Mermelstein PG. Caveolin proteins are essential for distinct effects of membrane estrogen receptors in neurons. *J Neurosci* 2007;27:9941–9950. [PubMed: 17855608]
35. Watters JJ, Campbell JS, Cunningham MJ, Krebs EG, Dorsa DM. Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription. *Endocrinology* 1997;138:4030–4033. [PubMed: 9275096]
36. Bixo M, Andersson A, Winblad B, Purdy RH, Backstrom T. Progesterone, 5alpha-pregnane-3,20-dione and 3alpha-hydroxy-5alpha-pregnane-20-one in specific regions of the human female brain in different endocrine states. *Brain Res* 1997;764:173–178. [PubMed: 9295207]
37. Rai D, Frolova A, Frasor J, Carpenter AE, Katzenellenbogen BS. Distinctive actions of membrane-targeted versus nuclear localized estrogen receptors in breast cancer cells. *Mol Endocrinol* 2005;19:1606–1617. [PubMed: 15831524]
38. Zheng J, Ramirez VD. Demonstration of membrane estrogen binding proteins in rat brain by ligand blotting using a 17beta-estradiol-[125I]bovine serum albumin conjugate. *J Steroid Biochem Mol Biol* 1997;62:327–336. [PubMed: 9408087]
39. Pietras RJ, Szego CM. Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. *Nature* 1977;265:69–72. [PubMed: 834244]
40. Razandi M, Pedram A, Greene GL, Levin ER. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. *Mol Endocrinol* 1999;13:307–319. [PubMed: 9973260]
41. Lee SJ, Campomanes CR, Sikat PT, Greenfield AT, Allen PB, McEwen BS. Estrogen induces phosphorylation of cyclic AMP response element binding (pCREB) in primary hippocampal cells in a time-dependent manner. *Neuroscience* 2004;124:549–560. [PubMed: 14980726]
42. Zhou Y, Watters JJ, Dorsa DM. Estrogen rapidly induces the phosphorylation of the cAMP response element binding protein in rat brain. *Endocrinology* 1996;137:2163–2166. [PubMed: 8612562]
43. Bulayeva NN, Wozniak AL, Lash LL, Watson CS. Mechanisms of membrane estrogen receptor-alpha-mediated rapid stimulation of Ca2 levels and prolactin release in a pituitary cell line. *Am J Physiol Endocrinol Metab* 2005;288:E388–E397. [PubMed: 15494610]
44. Abraham IM, Todman MG, Korach KS, Herbison AE. Critical in vivo roles for classical estrogen receptors in rapid estrogen actions on intracellular signaling in mouse brain. *Endocrinology* 2004;145:3055–3061. [PubMed: 14976146]
45. Levin ER. Integration of the extranuclear and nuclear actions of estrogen. *Mol Endocrinol* 2005;19:1951–1959. [PubMed: 15705661]
46. Vasudevan N, Pfaff DW. Membrane-initiated actions of estrogens in neuroendocrinology: emerging principles. *Endocr Rev* 2007;28:1–19. [PubMed: 17018839]
47. Choe ES, Wang JQ. Group I metabotropic glutamate receptor activation increases phosphorylation of cAMP response element-binding protein, Elk-1, and extracellular signal-regulated kinases in rat dorsal striatum. *Brain Res Mol Brain Res* 2001;94:75–84. [PubMed: 11597767]
48. Warwick HK, Nahorski SR, Challiss RA. Group I metabotropic glutamate receptors, mGlu1a and mGlu5a, couple to cyclic AMP response element binding protein (CREB) through a common Ca2+- and protein kinase C-dependent pathway. *J Neurochem* 2005;93:232–245. [PubMed: 15773922]
49. Razandi M, Alton G, Pedram A, Ghonshani S, Webb P, Levin ER. Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane. *Mol Cell Biol* 2003;23:1633–1646. [PubMed: 12588983]
50. Acconcia F, Ascenzi P, Bocedi A, Spisni E, Tomasi V, Trentalance A, Visca P, Marino M. Palmitoylation-dependent estrogen receptor alpha membrane localization: regulation by 17beta-estradiol. *Mol Biol Cell* 2005;16:231–237. [PubMed: 15496458]
51. Pedram A, Razandi M, Sainson RC, Kim JK, Hughes CC, Levin ER. A conserved mechanism for steroid receptor translocation to the plasma membrane. *J Biol Chem* 2007;282:22278–22288. [PubMed: 17535799]
52. Dewing P, Boulware MI, Sinchak K, Christensen A, Mermelstein PG, Micevych P. Membrane estrogen receptor-alpha interactions with metabotropic glutamate receptor 1a modulate female sexual receptivity in rats. *J Neurosci* 2007;27:9294–300. [PubMed: 17728443]

53. Chaban V, Li J, McDonald JS, Rapkin A, Micevych P. Estradiol attenuates ATP-induced increase of intracellular calcium through group II metabotropic glutamate receptors in rat DRG neurons. *Soc Neurosci Abstr* 2007;33:519.7.
54. Kuo J, Hariri OR, Bondar G, Ogi J, Micevych PE. Membrane estradiol receptors interact with metabotropic glutamate receptors to mobilize intracellular calcium in hypothalamic astrocytes. *Endocrinology*. 2008(in press)
55. Grove-Strawser, D.; Mermelstein, PG. Estrogen receptors activate different mGluRs across distinct brain regions. Abstract 195.13/XX10, in Society for Neuroscience Annual Meeting 2007; San Diego, CA. 2007.
56. Stefanova I, Horejsi V, Ansotegui IJ, Knapp W, Stockinger H. GPI-anchored cell-surface molecules complexed to protein tyrosine kinases. *Science* 1991;254:1016–1019. [PubMed: 1719635]
57. Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R, Grohe C. Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. *J Biol Chem* 2000;275:18447–18453. [PubMed: 10749889]
58. Etgen AM, Ansonoff MA, Quesada A. Mechanisms of ovarian steroid regulation of norepinephrine receptor-mediated signal transduction in the hypothalamus: implications for female reproductive physiology. *Horm Behav* 2001;40:169–177. [PubMed: 11534978]
59. Al-Chaer ED, Traub RJ. Biological basis of visceral pain: recent developments. *Pain* 2002;96:221–225. [PubMed: 11972993]
60. Quesada A, Micevych PE. Estrogen interacts with the IGF-1 system to protect nigrostriatal dopamine and maintain motoric behavior after 6-hydroxydopamine lesions. *J Neurosci Res* 2004;75:107–116. [PubMed: 14689453]
61. Micevych P, Ulibarri C. Development of the limbic–hypothalamic cholecystokinin circuit: a model of sexual differentiation. *Dev Neurosci* 1992;14:11–34. [PubMed: 1600878]
62. Sinchak K, Dewing P, Cook M, Micevych P. Release of orphanin FQ/nociceptin in the medial preoptic nucleus and ventromedial nucleus of the hypothalamus facilitates lordosis. *Horm Behav* 2007;51:406–412. [PubMed: 17274997]
63. Pfaff DW, Sakuma Y. Facilitation of the lordosis reflex of female rats from the ventromedial nucleus of the hypothalamus. *J Physiol* 1979;288:189–202. [PubMed: 469715]
64. Sawyer CH. Induction of estrus in the ovariectomized cat by local hypothalamic treatment with estrogen. *Anat Rec* 1963;145:280.
65. Gorski RA, Yanase M. Estrogen facilitation of lordosis behavior in the female rat. *Exp Brain Res* 1981;(Suppl 3):222–237. [PubMed: 7250245]
66. Bale TL, Dorsa DM. Regulation of oxytocin receptor messenger ribonucleic acid in the ventromedial hypothalamus by testosterone and its metabolites. *Endocrinology* 1995;136:5135–5138. [PubMed: 7588251]
67. Crowley RS, Insel TR, O'Keefe JA, Kim NB, Amico JA. Increased accumulation of oxytocin messenger ribonucleic acid in the hypothalamus of the female rat: induction by long term estradiol and progesterone administration and subsequent progesterone withdrawal. *Endocrinology* 1995;136:224–231. [PubMed: 7828535]
68. Micevych PE, Abelson L, Fok H, Ulibarri C, Priest CA. Gonadal steroid control of preprocholecystokinin mRNA expression in the limbic-hypothalamic circuit: comparison of adult with neonatal steroid treatments. *J Neurosci Res* 1994;38:386–398. [PubMed: 7932871]
69. Priest CA, Eckersell CB, Micevych PE. Estrogen regulates preproenkephalin-A mRNA levels in the rat ventromedial nucleus: temporal and cellular aspects. *Brain Res Mol Brain Res* 1995a;28:251–262. [PubMed: 7723624]
70. Priest CA, Vink KL, Micevych PE. Temporal regulation by estrogen of beta-preprotachykinin mRNA expression in the rat ventromedial nucleus of the hypothalamus. *Brain Res Mol Brain Res* 1995b;28:61–71. [PubMed: 7707879]
71. Romano GJ, Mobbs CV, Lauber A, Howells RD, Pfaff DW. Differential regulation of proenkephalin gene expression by estrogen in the ventromedial hypothalamus of male and female rats: implications for the molecular basis of a sexually differentiated behavior. *Brain Res* 1990;536:63–68. [PubMed: 1707724]
72. Wilcox JN, Roberts JL. Estrogen decreases rat hypothalamic proopiomelanocortin messenger ribonucleic acid levels. *Endocrinology* 1985;117:2392–2396. [PubMed: 2933246]

73. Kow LM, Pfaff DW. The membrane actions of estrogens can potentiate their lordosis behavior-facilitating genomic actions. *Proc Natl Acad Sci U S A* 2004;101:12354–12357. [PubMed: 15302933]
74. Mills RH, Sohn RK, Micevych PE. Estrogen-induced mu-opioid receptor internalization in the medial preoptic nucleus is mediated via neuropeptide Y-Y1 receptor activation in the arcuate nucleus of female rats. *J Neurosci* 2004;24:947–955. [PubMed: 14749439]
75. Eckersell CB, Popper P, Micevych PE. Estrogen-induced alteration of mu-opioid receptor immunoreactivity in the medial preoptic nucleus and medial amygdala. *J Neurosci* 1998;18:3967–3976. [PubMed: 9570823]
76. Sinchak K, Micevych PE. Progesterone blockade of estrogen activation of mu-opioid receptors regulates reproductive behavior. *J Neurosci* 2001;21:5723–5729. [PubMed: 11466444]
77. Sinchak K, Hendricks DG, Baroudi R, Micevych PE. Orphanin FQ/nociceptin in the ventromedial nucleus facilitates lordosis in female rats. *Neuroreport* 1997;8:3857–3860. [PubMed: 9462455]
78. Torii M, Kubo K. The effects of intraventricular injection of beta-endorphin on initial estrogen action to induce lordosis behavior. *Physiol Behav* 1994;55:157–162. [PubMed: 8140161]
79. Herbison, AE. Physiology of the gonadotropin-releasing hormone network. In: Neill, JD., editor. *Physiology of reproduction*. Elsevier; Amsterdam: 2006. p. 1415-1482.
80. Ronnekleiv OK, Kelly MJ. Diversity of ovarian steroid signaling in the hypothalamus. *Front Neuroendocrinol* 2005;26:65–84. [PubMed: 16009409]
81. Micevych P, Soma KK, Sinchak K. Neuroprogesterone: key to estrogen positive feedback? *Brain Res Rev* 2008;57:470–480. [PubMed: 17850878]
82. Schumacher, M.; Robert, F. Progesterone: synthesis, metabolism, mechanisms of action, and effects in the nervous system. In: Pfaff, DW.; Arnold, AP.; Etgen, AM.; Fahrbach, SE.; Rubin, RT., editors. *Hormones, brain and behavior*. Academic; Amsterdam: 2002. p. 683-745.
83. Callachan H, Cottrell GA, Hather NY, Lambert JJ, Nooney JM, Peters JA. Modulation of the GABAA receptor by progesterone metabolites. *Proc R Soc Lond B Biol Sci* 1987;231:359–369. [PubMed: 2888123]
84. Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. *Science* 1986;232:1004–1007. [PubMed: 2422758]
85. Zwain IH, Yen SS. Neurosteroidogenesis in astrocytes, oligodendrocytes, and neurons of cerebral cortex of rat brain. *Endocrinology* 1999;140:3843–3852. [PubMed: 10433246]
86. Micevych PE, Chaban V, Ogi J, Dewing P, Lu JK, Sinchak K. Estradiol stimulates progesterone synthesis in hypothalamic astrocyte cultures. *Endocrinology* 2007;148:782–789. [PubMed: 17095591]
87. Sinchak K, Mills RH, Tao L, LaPolt P, Lu JK, Micevych P. Estrogen induces de novo progesterone synthesis in astrocytes. *Dev Neurosci* 2003;25:343–348. [PubMed: 14614261]
88. Micevych P, Sinchak K, Mills RH, Tao L, LaPolt P, Lu JK. The luteinizing hormone surge is preceded by an estrogen-induced increase of hypothalamic progesterone in ovariectomized and adrenalectomized rats. *Neuroendocrinology* 2003;78:29–35. [PubMed: 12869797]
89. Alila HW, Davis JS, Dowd JP, Corradino RA, Hansel W. Differential effects of calcium on progesterone production in small and large bovine luteal cells. *J Steroid Biochem* 1990;36:687–693. [PubMed: 2170770]
90. Rao MC, Palfrey HC, Nash NT, Greisman A, Jayatilak PG, Gibori G. Effects of estradiol on calcium-specific protein phosphorylation in the rat corpus luteum. *Endocrinology* 1987;120:1010–1018. [PubMed: 3803307]
91. Shalem Z, Izhar M, Shore LS, Shemesh M, Hansel W, Strauss JF III. Control of bovine placental progesterone synthesis: calcium dependent steroidogenesis is modulated at the site of the cholesterol side chain cleavage enzyme. *J Steroid Biochem* 1988;31:835–838. [PubMed: 2462134]
92. Shemesh M, Hansel W, Strauss JF III. Calcium-dependent, cyclic nucleotide-independent steroidogenesis in the bovine placenta. *Proc Natl Acad Sci U S A* 1984;81:6403–6407. [PubMed: 6208549]
93. Burnstock G. Purine-mediated signalling in pain and visceral perception. *Trends Pharmacol Sci* 2001;22:182–188. [PubMed: 11282418]

94. Dunn PM, Zhong Y, Burnstock G. P2X receptors in peripheral neurons. *Prog Neurobiol* 2001;65:107–134. [PubMed: 11403876]
95. Koshimizu TA, Van Goor F, Tomic M, Wong AO, Tanoue A, Tsujimoto G, Stojilkovic SS. Characterization of calcium signaling by purinergic receptor-channels expressed in excitable cells. *Mol Pharmacol* 2000;58:936–945. [PubMed: 11040040]
96. Bodin P, Burnstock G. Purinergic signalling: ATP release. *Neurochem Res* 2001;26:959–969. [PubMed: 11699948]
97. Chen CC, Akopian AN, Sivilotti L, Colquhoun D, Burnstock G, Wood JN. A P2X purinoceptor expressed by a subset of sensory neurons. *Nature* 1995;377:428–431. [PubMed: 7566119]
98. Ueno S, Tsuda M, Iwanaga T, Inoue K. Cell type-specific ATP-activated responses in rat dorsal root ganglion neurons. *Br J Pharmacol* 1999;126:429–436. [PubMed: 10077235]
99. Cockayne DA, Hamilton SG, Zhu QM, Dunn PM, Zhong Y, Novakovic S, Malmberg AB, Cain G, Berson A, Kassotakis L, Hedley L, Lachnit WG, Burnstock G, McMahon SB, Ford AP. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. *Nature* 2000;407:1011–1015. [PubMed: 11069181]
100. Zhong Y, Dunn PM, Bardini M, Ford AP, Cockayne DA, Burnstock G. Changes in P2X receptor responses of sensory neurons from P2X3-deficient mice. *Eur J Neurosci* 2001;14:1784–1792. [PubMed: 11860473]
101. Papka RE, Storey-Workley M. Estrogen receptor-alpha and -beta coexist in a subpopulation of sensory neurons of female rat dorsal root ganglia. *Neurosci Lett* 2002;319:71–74. [PubMed: 11825673]
102. Chaban VV, Mayer EA, Ennes HS, Micevych PE. Estradiol inhibits ATP-induced intracellular calcium concentration increase in dorsal root ganglia neurons. *Neuroscience* 2003;118:941–948. [PubMed: 12732239]
103. Riley JL III, Robinson ME, Wise EA, Myers CD, Fillingim RB. Sex differences in the perception of noxious experimental stimuli: a meta-analysis. *Pain* 1998;74:181–187. [PubMed: 9520232]
104. Sapsed-Byrne S, Ma D, Ridout D, Holdcroft A. Estrous cycle phase variations in visceromotor and cardiovascular responses to colonic distension in the anesthetized rat. *Brain Res* 1996;742:10–16. [PubMed: 9117383]
105. Traub RJ, Murphy A. Colonic inflammation induces fos expression in the thoracolumbar spinal cord increasing activity in the spinoparabrachial pathway. *Pain* 2002;95:93–102. [PubMed: 11790471]
106. Lee SJ, McEwen BS. Neurotrophic and neuroprotective actions of estrogens and their therapeutic implications. *Annu Rev Pharmacol Toxicol* 2001;41:569–91. [PubMed: 11264469]
107. Sand P. Chronic pain syndromes of gynecologic origin. *J Reprod Med* 2004;49:230–234. [PubMed: 15088861]
108. McRoberts JA, Coutinho SV, Marvizon JC, Grady EF, Tognetto M, Sengupta JN, Ennes HS, Chaban VV, Amadesi S, Creminon C, Lanthorn T, Geppetti P, Bunnett NW, Mayer EA. Role of peripheral N-methyl-D-aspartate (NMDA) receptors in visceral nociception in rats. *Gastroenterology* 2001;120:1737–1748. [PubMed: 11375955]
109. Aloisi AM, Ceccarelli I, Herdegen T. Gonadectomy and persistent pain differently affect hippocampal c-Fos expression in male and female rats. *Neurosci Lett* 2000;281:29–32. [PubMed: 10686408]
110. Amandusson A, Hallbeck M, Hallbeck AL, Hermanson O, Blomqvist A. Estrogen-induced alterations of spinal cord enkephalin gene expression. *Pain* 1999;83:243–248. [PubMed: 10534596]
111. Williams SJ, Papka RE. Estrogen receptor-immunoreactive neurons are present in the female rat lumbosacral spinal cord. *J Neurosci Res* 1996;46:492–501. [PubMed: 8950709]
112. Papka RE, Storey-Workley M, Shughrue PJ, Merchenthaler I, Collins JJ, Usip S, Saunders PT, Shupnik M. Estrogen receptor-alpha and beta-immunoreactivity and mRNA in neurons of sensory and autonomic ganglia and spinal cord. *Cell Tissue Res* 2001;304:193–214. [PubMed: 11396714]
113. Taleghany N, Sarajari S, DonCarlos LL, Gollapudi L, Oblinger MM. Differential expression of estrogen receptor alpha and beta in rat dorsal root ganglion neurons. *J Neurosci Res* 1999;57:603–615. [PubMed: 10462685]

114. Lee DY, Chai YG, Lee EB, Kim KW, Nah SY, Oh TH, Rhim H. 17Beta-estradiol inhibits high-voltage-activated calcium channel currents in rat sensory neurons via a non-genomic mechanism. *Life Sci* 2002;70:2047–2059. [PubMed: 12148697]
115. Martinez-Gomez M, Cruz Y, Salas M, Hudson R, Pacheco P. Assessing pain threshold in the rat: changes with estrus and time of day. *Physiol Behav* 1994;55:651–657. [PubMed: 8190790]
116. Giamberardino MA, Affaitati G, Valente R, Iezzi S, Vecchiet L. Changes in visceral pain reactivity as a function of estrous cycle in female rats with artificial ureteral calculosis. *Brain Res* 1997;774:234–238. [PubMed: 9452216]
117. Holdcroft A. Hormones and the gut. *Br J Anaesth* 2000;85:58–68. [PubMed: 10927995]
118. Berkley KJ. Sex differences in pain. *Behav Brain Sci* 1997;20:371–80. [PubMed: 10097000] (discussion 435–513)
119. Fillingim RB, Ness TJ. Sex-related hormonal influences on pain and analgesic responses. *Neurosci Biobehav Rev* 2000;24:485–501. [PubMed: 10817845]
120. Kim YJ, Hur EM, Park TJ, Kim KT. Nongenomic inhibition of catecholamine secretion by 17beta-estradiol in PC12 cells. *J Neurochem* 2000;74:2490–2496. [PubMed: 10820210]
121. Kurata K, Takebayashi M, Kagaya A, Morinobu S, Yamawaki S. Effect of beta-estradiol on voltage-gated Ca(2) channels in rat hippocampal neurons: a comparison with dehydroepiandrosterone. *Eur J Pharmacol* 2001;416:203–212. [PubMed: 11290370]
122. Chaban VV, Micevych PE. Estrogen receptor-alpha mediates estradiol attenuation of ATP-induced Ca2 signaling in mouse dorsal root ganglion neurons. *J Neurosci Res* 2005;81:31–37. [PubMed: 15952176]

Fig. 1.

Estrogen receptor activation of mGluR signaling through interactions with caveolin proteins.

a Model framework of estradiol-induced activation of mGluRs via caveolin-based caveolae.

b Summary of previous findings demonstrating estrogen receptor activation of group I (mGluR1/5) and group II (mGluR2/3) metabotropic glutamate receptors is mediated by caveolin 1 and caveolin 3, respectively

Fig. 2.

Direct ER/mGluR interactions may underlie estradiol-induced activation of mGluRs. **a** Co-immunoprecipitation of endogenous ER α with mGluR1a in cultured hippocampal neurons. **b** Antagonism of ERs with ICI 182,780 attenuates CREB phosphorylation following the application of the group I mGluR agonist DHPG. **c** ICI 182,780 has no effect on CREB phosphorylation in cultures generated from male tissue, which lack the mGluR-mediated estrogen response

Fig. 3.

ER/mGluR signaling in the arcuate nucleus (ARH)–medial preoptic nucleus (MPN) circuit regulates female sexual receptivity. **a** When circulating levels of estradiol are low, the circuit is not activated and the rat is not sexually receptive. **b** When circulating levels of estradiol are increased, estrogen receptors in the ARH are stimulated. A population of estrogen receptors, located on the plasma membrane, induces the release of β -endorphin in the MPN from ARH projection neurons activating and internalizing MORs, producing lordosis. **c** If mGluR1a is stimulated in the presence of low circulating estradiol concentrations, the ARH–MPN projection is activated: MORs are activated/internalized and lordosis is displayed. **d** Conversely, when mGluR1a is antagonized in the presence of high levels of circulating

estrogen, the ARH–MPN circuit is not activated: MORs are not internalized and lordosis is attenuated

Fig. 4.

Proposed mechanism through which estradiol signaling in astrocytes is integrated with local neuronal activity involved in the synthesis of neuroprogesterone. Estradiol (E₂), typically of ovarian origin, binds to membrane ERα and activates the mGluR1a. This increases levels of free cytoplasmic calcium (Ca²⁺) through the inositol trisphosphate (IP₃) receptor-mediated release of intracellular stores of calcium. Elevated levels of intracellular Ca²⁺ are needed for neuroprogesterone (P₄) synthesis in astrocytes. Studies in vitro demonstrate that E₂ alone or an mGluR1a agonist alone increase intracellular calcium levels. However, when both an mGluR1a agonist and E₂ are applied to astrocytes, the resulting Ca²⁺ flux is significantly greater, suggesting that P₄ synthesis is also augmented. We propose that in vivo when E₂-stimulated astrocytes are in the proximity of active nerve terminals, the released glutamate (Glu) activates astrocyte mGluR1a, resulting in significantly greater Ca²⁺ responses. This elevated Ca²⁺ response is hypothesized to produce a greater P₄ synthesis in astrocytes.